Currently, there are 53.94M common shares owned by the public and among those 45.46M shares have been available to trade.
The company’s stock has a 5-day price change of -9.38% and 9.39% over the past three months. FULC shares are trading -15.74% year to date (YTD), with the 12-month market performance down to -45.60% lower. It has a 12-month low price of $2.86 and touched a high of $13.70 over the same period. FULC has an average intraday trading volume of 890.16K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -11.71%, -0.44%, and -35.01% respectively.
Institutional ownership of Fulcrum Therapeutics Inc (NASDAQ: FULC) shares accounts for 91.13% of the company’s 53.94M shares outstanding.
It has a market capitalization of $213.60M and a beta (3y monthly) value of 2.05. The earnings-per-share (ttm) stands at -$0.31. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.86% over the week and 8.18% over the month.
Earnings per share for the fiscal year are expected to increase by 90.67%, and -610.11% over the next financial year.
Looking at the support for the FULC, a number of firms have released research notes about the stock. H.C. Wainwright stated their Neutral rating for the stock in a research note on September 13, 2024, with the firm’s price target at $17-$4. RBC Capital Mkts was of a view on September 12, 2024 that the stock is Sector Perform, while Leerink Partners gave the stock Market Perform rating on September 12, 2024, issuing a price target of $4. Cantor Fitzgerald on their part issued Neutral rating on September 12, 2024.
